Personalized Therapy Management for Coronary Artery Disease
(PARAMOUNT Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Cleerly Labs and Cleerly ISCHEMIA for coronary artery disease?
Research on personalized medicine in cardiovascular disease suggests that tailoring treatments based on individual characteristics, such as genetic or demographic factors, can improve outcomes. This approach has been used in other cardiovascular conditions, indicating potential benefits for personalized therapy management in coronary artery disease.12345
Is there any safety data available for personalized therapy management for coronary artery disease?
How is the treatment Cleerly Labs and Cleerly ISCHEMIA unique for coronary artery disease?
This treatment is unique because it uses personalized therapy management, which involves tailoring the treatment to the individual patient's genetic and proteomic profile. This approach aims to identify patients who are most likely to benefit from the treatment and those who might experience adverse reactions, making it more precise compared to standard treatments.145910
What is the purpose of this trial?
PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary atherosclerotic plaque assessment by AI-enabled quantitative software improves: certainty for diagnosis of CAD, control of CAD risk factors and efficiency of ICA referral with appropriate PCI compared to the usual care strategy based on current AHA/ACC guidelines for care of symptomatic patients with suspicion of CAD.
Research Team
Todd Villines, MD
Principal Investigator
University of Virginia
Maros Ferencik, MD
Principal Investigator
Oregon Health and Science University
Eligibility Criteria
This trial is for people with symptoms suggesting they might have coronary artery disease (CAD). They should be candidates for a CT scan to check their heart arteries. The study excludes those who can't undergo CT scans, are pregnant, or have other serious health issues that could interfere with the trial.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive personalized management based on coronary plaque assessment or usual care
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cleerly Labs and Cleerly ISCHEMIA
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cleerly, Inc.
Lead Sponsor